FATE Therapeutics (NASDAQ: FATE) director receives 87,900-share stock option grant

Rhea-AI Filing Summary

FATE Therapeutics director Matt Abernethy received a new stock option grant covering 87,900 shares of common stock. The option has an exercise price of $2.06 per share and expires on June 12, 2036.

The grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides annual equity awards on the date of the Annual Meeting of Stockholders. These options vest and become exercisable on the earlier of June 12, 2027 or the date of the 2027 Annual Meeting, as long as Abernethy continues to serve on the board.

Insights

Equity compensation analyst

Routine director option grant with time-based vesting and long-dated term.

The filing shows a standard compensation-related award rather than an open-market trade. Director Matt Abernethy received options on 87,900 shares at an exercise price of $2.06, expiring in 2036, aligning his incentives with long-term shareholder value.

Vesting is time-based and tied to continued board service until the earlier of June 12, 2027 or the 2027 Annual Meeting of Stockholders. With no sales reported and no 10b5-1 language noted, this appears to be a routine annual equity grant to a non-employee director.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ABERNETHY MATT

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	87,900	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 87,900 shares (Direct, null)

Footnotes (1)

1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Key Figures

Option grant size: 87,900 shares Exercise price: $2.06 per share Expiration date: June 12, 2036 +2 more

5 metrics

Option grant size 87,900 shares Stock Option (Right to Buy) granted to director

Exercise price $2.06 per share Conversion or exercise price of stock option

Expiration date June 12, 2036 Option term end for director grant

Vesting date June 12, 2027 Earlier of this date or 2027 Annual Meeting

Shares following transaction 87,900 derivative shares Total options held from this grant after transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Amended and Restated Non-Employee Director Compensation Policy, Annual Meeting of Stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Amended and Restated Non-Employee Director Compensation Policy financial

"represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy"

Annual Meeting of Stockholders financial

"annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders"

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 04:08 PM Accepted by SEC EDGAR 06/15/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ABERNETHY MATT

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.06	06/12/2026		A(1)		87,900		(2)	06/12/2036	Common Stock	87,900	$0	87,900	D

Explanation of Responses:

1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

2. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

	/s/ Cindy Tahl, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Matt Abernethy acquire in this Form 4 for FATE?

Matt Abernethy received a grant of stock options covering 87,900 shares of FATE Therapeutics common stock. These options were awarded as part of the company’s non-employee director compensation policy on the date of the Annual Meeting of Stockholders.

What is the exercise price of Matt Abernethy’s FATE stock options?

The exercise price of Matt Abernethy’s new stock options is $2.06 per share. This means he can buy FATE Therapeutics common stock at $2.06 once the options vest and become exercisable, subject to the vesting conditions disclosed.

When do Matt Abernethy’s FATE stock options vest?

The options vest and become exercisable on the earlier of June 12, 2027 or the date of FATE Therapeutics’ 2027 Annual Meeting of Stockholders. Vesting is contingent on Abernethy’s continued service on the company’s board of directors.

How many FATE shares are subject to Matt Abernethy’s option grant?

The option grant covers 87,900 shares of FATE Therapeutics common stock. This is a derivative award, meaning Abernethy gains the right to purchase these shares at the fixed exercise price if and when the options vest and he chooses to exercise.

Is Matt Abernethy’s Form 4 transaction a market purchase or sale of FATE stock?

No, the Form 4 reflects a grant of stock options, not an open-market purchase or sale. The transaction is coded as a grant or award, providing the right to buy shares at $2.06 in the future after vesting, rather than immediate share trading.

What company policy governs Matt Abernethy’s FATE option grant?

The grant was made under FATE Therapeutics’ Amended and Restated Non-Employee Director Compensation Policy. This policy provides for annual equity grants to non-employee directors on the date of the company’s Annual Meeting of Stockholders, aligning compensation with shareholder interests.